Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 6167345, 5 pages
https://doi.org/10.1155/2017/6167345
Case Report

Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case

1Hematology Division, IRCCS Ca’ Granda-Maggiore Policlinico Hospital Foundation and University of Milan, Milan, Italy
2Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seragnoli,” University of Bologna, Bologna, Italy

Correspondence should be addressed to Alessandra Iurlo; ti.im.ocinilcilop@olruia

Received 11 April 2017; Revised 19 June 2017; Accepted 12 July 2017; Published 14 August 2017

Academic Editor: Stephen Langabeer

Copyright © 2017 Cristina Bucelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Cristina Bucelli, Daniele Cattaneo, Valeria Ferla, et al., “Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case,” Case Reports in Hematology, vol. 2017, Article ID 6167345, 5 pages, 2017. https://doi.org/10.1155/2017/6167345.